FDA Brief

Warning letters Drugs

FDA warning letter to

Aeroflex Industria de Aerosol Ltda.

High riskIssued May 22Posted Jun 2Center for Drug Evaluation and Research (CDER)

Brazil OTC drug maker Aeroflex ignored FDA records requests, prompting possible approval holds and US shipment refusals.

What happened

FDA says Aeroflex is registered as an OTC drug manufacturer, and previous correspondence indicated it makes and imports multiple drug products; one product is sold on online marketplaces. On October 27, 2025, FDA emailed a request for records and other information under section 704(a)(4) to the registration contact, and the request and numerous follow-ups went unanswered. FDA says it therefore has no indication of the quality assurance level for drugs listed as manufactured at the facility.

What FDA found

  1. The company did not answer FDA's electronic request for records and other information about its drug manufacturing.

    section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))
  2. Refusing to permit access to or copying of required records is a prohibited act.

    section 301(e) of the FD&C Act (21 U.S.C. 331(e))
  3. The company also did not answer numerous follow-up requests from FDA.

What FDA wants

Within 15 working days, respond in writing to confirm or update the company's registration and/or drug listing status and say whether it will answer the records request. If Aeroflex no longer makes drugs, FDA asks it to delist all previously listed drugs using the last lot expiration date as the marketing end date and deregister the facility.

Who should pay attention

  • US importers and distributors of Aeroflex OTC drugs
  • brands and online sellers sourcing products made by this facility
  • companies listing Aeroflex as a drug manufacturer in FDA applications

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Zhao Qing Longda Biotechnology Co. Ltd.

    FDA says Zhao Qing Longda Biotechnology refused records access for OTC drugs, including children’s toothpaste, and placed its drugs on import alert.

    High risk
  2. KM Pharmaceutical Co. Ltd.

    FDA says KM Pharmaceutical refused to provide drug records and placed all its drugs on import alert.

    High risk
  3. The Anthos Group, Inc.

    Anthos Group refused FDA access to OTC drug records for VERTRA Hand Sanitizer, FDA says.

    Medium
  4. True Chemical Solutions, LLC

    FDA cites True Chemical Solutions over unanswered hand sanitizer records requests.

    Medium